TriangleNCT05256381 · REGISTRY CONDITION SEARCH
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.
- Phase
- PHASE2
- Status at capture
- TERMINATED
- Registry last update
- 2025-11-17
The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa in combination with pembrolizumab in selected tumors.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Percentage of Patients With Objective Response Rate According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)
Number of Patients With a Treatment-emergent Adverse Event
Number of Patients With an Adverse Event of Special Interest
Percentage of Patients With Objective Response Rate According to RECIST for Immune-based Therapeutics (iRECIST)
Number of Patients With Best Overall Response According to RECIST 1.1: Complete Response
Number of Patients With Best Overall Response According to RECIST 1.1: Partial Response
Number of Patients With Best Overall Response According to RECIST 1.1: Stable Disease
Number of Patients With Best Overall Response According to RECIST 1.1: Progressive Disease
Number of Patients With Best Overall Response According to iRECIST: Complete Response
Number of Patients With Best Overall Response According to iRECIST: Partial Response
Number of Patients With Best Overall Response According to iRECIST: Stable Disease
Number of Patients With Best Overall Response According to iRECIST: Unconfirmed Progressive Disease
Number of Patients With Best Overall Response According to iRECIST: Confirmed Progressive Disease
Duration of Response According to RECIST 1.1
Duration of Response According to iRECIST
Percentage of Patients With Clinical Benefit Rate According to RECIST 1.1
Percentage of Patients With Clinical Benefit Rate According to iRECIST
Progression-free Survival According to RECIST 1.1
Progression-free Survival According to iRECIST
Time to Response According to RECIST 1.1
Time to Response According to iRECIST
Duration of Response According to Prostate Cancer Clinical Trials Working Group 3 Modified RECIST 1.1
Percentage of Patients With Clinical Benefit Rate According to Prostate Cancer Clinical Trials Working Group 3 Modified RECIST 1.1
Progression-free Survival According to Prostate Cancer Clinical Trials Working Group 3 Modified RECIST 1.1
Percentage of Patients With Circulating Tumor Cell Count Conversion as Assessed According to Prostate Cancer Clinical Trials Working Group 3 Modified RECIST 1.1
Percentage of Patients With Confirmed Prostate-specific Antigen Decline of ≥50% as Assessed According to Prostate Cancer Clinical Trials Working Group 3 Modified RECIST 1.1
Time to Confirmed Prostate-specific Antigen Progression as Assessed According to Prostate Cancer Clinical Trials Working Group 3 Modified RECIST 1.1
Nanrilkefusp Alfa Concentration Profile, Cycle 1 Day 1, 30 (+/-5) Minutes After Nanrilkefusp Alfa Administration
Nanrilkefusp Alfa Concentration Profile, Cycle 1 Day 1, 2 Hours (+/-15 Minutes) After Nanrilkefusp Alfa Administration
Number of Patients With Anti-drug Antibodies, Cycle 4 Day 1
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Participants with the following histologically or cytologically confirmed solid tumor indications and line of treatment: 1. Non-small cell lung cancer (NSCLC). 2. Colorectal cancer. 3. Cutaneous squamous cell carcinoma (cSCC). 4. Advanced hepatocellular carcinoma (not applicable in France). 5. mCRPC. 6. Ovarian cancer. * Have measurable disease per RECIST 1.1. mCRPC participants with no measurable disease and only widespread bone disease must have a CTC count of ≥5 cells per 7.5 mL of blood. * Availability of tumor tissue from a fresh biopsy at screening unless the biopsy cannot be obtained due to safety reasons or non-accessibility of the tumor site. If it is not possible to obtain a fresh biopsy, every effort should be taken to retrieve an archival biopsy. Archived, fixed tumor tissue may only be collected if taken preferentially after completion of the most recent systemic tumor therapy and within 12 months prior to the first dose of study treatment. * Eastern Cooperative Oncology Group (ECOG) score 0-1. * Have recovered from all AEs (except alopecia) due to previous therapies to grade ≤1 (excluding alopecia) or have stable grade 2 neuropathy. * Have adequate organ function as defined below: 1. Hematology: 1. Absolute neutrophil count ≥1500/μL. 2. Platelets ≥100 000/μL. 3. Hemoglobin ≥9.0 g/dL . 2. Renal function: Creatinine clearance as measured by glomerular filtration rate ≥30 mL/min using Cockcroft-Gault equation. 3. Hepatic function: Alanine transaminase (ALT)/aspartate transaminase (AST) ≤2.5× upper limit of normal (ULN) and total bilirubin ≤1.5×ULN or direct bilirubin ≤ ULN in participants without liver metastasis. In participants with liver metastasis, ALT/AST ≤5×ULN is allowed but total bilirubin must be ≤2×ULN. 4. Prothrombin time and activated partial thromboplastin time ≤1.5×ULN. * Participants must not have active hepatitis B or hepatitis C infection. * Adequate contraception must be applied in all women of childbearing potential (WOCBP) and in male participants. Exclusion Criteria: * Has received prior therapy with an anti-programmed cell death protein 1 (anti-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), or anti-programmed cell death ligand 2 (anti-PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor and was discontinued from that treatment due to a grade ≥3 AE. * Prior exposure to agonists of interleukin (IL)-2 or IL-15. * Prior systemic anti-cancer therapies, including investigational agents: 1. Less than 4 weeks for systemic chemotherapy and immuno-oncology therapies; and for tyrosine kinase inhibitors 4 weeks or 5 half-lives (whichever is shorter). 2. Less than 4 weeks from major surgeries and not recovered adequately. * Has received prior radiotherapy within 2 weeks of the start of study interventions or have had a history of radiation pneumonitis. * NSCLC indication only: Received radiation therapy to the lung \>30 Gy within 6 months. * Has received a live or live-attenuated vaccine within 30 days. * Clinically significant cardiac abnormalities including prior history of any of the following: 1. Cardiomyopathy, with left ventricular ejection fraction ≤ 50%. 2. Congestive heart failure of New York Heart Association grade ≥2. 3. History of clinically significant artery or coronary heart disease. 4. Prolongation of QTcF \>450 msec . 5. Clinically significant cardiac arrythmia that cannot be controlled with adequate medication. * Uncontrolled hypertension defined as systolic blood pressure \>160 mmHg, diastolic blood pressure \>110 mmHg. * Prior allogeneic hematopoietic stem cell transplantation within the last 5 years. * Prior allogeneic tissue/solid organ transplant. * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy. * History of or serology positive for human immunodeficiency virus (HIV). * Has a known additional malignancy that is progressing or has required active treatment within the past 5 years, except for basal cell carcinoma of the skin or carcinoma in situ that have undergone potentially curative therapy are not excluded. * Has known active central nervous system metastases and/or carcinomatous meningitis, unless stable. * Had severe hypersensitivity (grade ≥3) to pembrolizumab and/or any of its excipients. * Has an active autoimmune disease that has required systemic treatment in the past 2 years. * History of (non-infectious) pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease. * Has an active infection requiring systemic therapy. * Has any condition that might confound the results of the study or interfere with the participant's participation for the full duration of the study.
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Participants will be treated with 12 μg/kg of nanrilkefusp alfa on Day 1, Day 2, Day 8, and Day 9 of each 3-week cycle in combination with 200 mg pembrolizumab on Day 1 of each 3-week cycle.
- intervention Names
- Drug: Nanrilkefusp Alfa
- Drug: Pembrolizumab
- label
- Nanrilkefusp Alfa and Pembrolizumab
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Nanrilkefusp Alfa and Pembrolizumab
- description
- Subcutaneous (SC) injection.
- name
- Nanrilkefusp Alfa
- other Names
- SOT101
- type
- DRUG
- arm Group Labels
- Nanrilkefusp Alfa and Pembrolizumab
- description
- Intravenous (IV) infusion via peripheral or central venous line.
- name
- Pembrolizumab
- other Names
- KEYTRUDA®
- type
- DRUG
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 166
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- measure
- Percentage of Patients With Objective Response Rate According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)
- time Frame
- Day 1 up to approximately 2 years and 2 months
- secondary Outcomes
- measure
- Number of Patients With a Treatment-emergent Adverse Event
- time Frame
- Day 1 up to approximately 2 years and 2 months
- measure
- Number of Patients With an Adverse Event of Special Interest
- time Frame
- Day 1 up to approximately 2 years and 2 months
- measure
- Percentage of Patients With Objective Response Rate According to RECIST for Immune-based Therapeutics (iRECIST)
- time Frame
- Day 1 up to approximately 2 years and 2 months
- measure
- Number of Patients With Best Overall Response According to RECIST 1.1: Complete Response
- time Frame
- Day 1 up to approximately 2 years and 2 months
- measure
- Number of Patients With Best Overall Response According to RECIST 1.1: Partial Response
- time Frame
- Day 1 up to approximately 2 years and 2 months
- measure
- Number of Patients With Best Overall Response According to RECIST 1.1: Stable Disease
- time Frame
- Day 1 up to approximately 2 years and 2 months
- measure
- Number of Patients With Best Overall Response According to RECIST 1.1: Progressive Disease
- time Frame
- Day 1 up to approximately 2 years and 2 months
- measure
- Number of Patients With Best Overall Response According to iRECIST: Complete Response
- time Frame
- Day 1 up to approximately 2 years and 2 months
- measure
- Number of Patients With Best Overall Response According to iRECIST: Partial Response
- time Frame
- Day 1 up to approximately 2 years and 2 months
- measure
- Number of Patients With Best Overall Response According to iRECIST: Stable Disease
- time Frame
- Day 1 up to approximately 2 years and 2 months
- measure
- Number of Patients With Best Overall Response According to iRECIST: Unconfirmed Progressive Disease
- time Frame
- Day 1 up to approximately 2 years and 2 months
- measure
- Number of Patients With Best Overall Response According to iRECIST: Confirmed Progressive Disease
- time Frame
- Day 1 up to approximately 2 years and 2 months
Full study description
- brief Summary
- The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa in combination with pembrolizumab in selected tumors.
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-1336d216cbd1bbff780dac70
- edge id
- nct-edge-ef6222cbc36bf60b46b9
- requested nct id
- NCT05256381
- primary nct id
- NCT05256381
- source kind
- ctgov_condition_query
- source record id
- Source null
- source file sha256
- 69c40ed34b17434f684079ec5635264bc5ad292871a86b835704fc99fa9d8157
- payload sha256
- 86fd439e74c8a23bea6964fc2f61d3330a61a7168b79b76ad43807d308f7f058
- payload
- clinical indication matching status
- condition_index_match_asserted_by_registry_not_reviewed
- end exclusive
- true
- id
- nct-edge-ef6222cbc36bf60b46b9
- link basis
- returned_by_explicit_condition_and_posted_results_filter_query
- nct id
- NCT05256381
- occurrences
- context exact
- NCT05256381
- end
- 11
- exact text
- NCT05256381
- start
- 0
- offset unit
- unicode_code_points
- query cond
- Small Intestine Cancer
- query disease state id
- ds-small-intestine-cancer
- source file
- /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-small-intestine-cancer-000.json
- source file sha256
- 69c40ed34b17434f684079ec5635264bc5ad292871a86b835704fc99fa9d8157
- source json pointer
- /studies/57/protocolSection/identificationModule/nctId
- source kind
- ctgov_condition_query
- source record id
- Source null
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- cdc3712bcfc5e8f68138feab31dd6405c2f9c0ed529730e7609fcaae768d0e70
Preserved source evidence · Not medical advice